Medical Oncology

ESMO 2023

Questions discussed in this category

What are your top takeaways from ESMO 2023?

9 Answers available

Papers discussed in this category

JAMA network open, 2023 Nov 01

Pembrolizumab Plus Chemotherapy Followed by Pembrolizumab in Patients With Early Triple-Negative Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.

The New England journal of medicine, 2023 Jun 04

Overall Survival with Osimertinib in Resected -Mutated NSCLC.

Nature medicine, 2023 Sep 14

Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial.

The New England journal of medicine, 2023 Oct 20

Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer.

Annals of oncology : official journal of the European Society for Medical Oncology, 2023 Oct 05

The Double Antibody Drug conjugate (DAD) Phase I trial: Sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma.

Lancet (London, England), 2009-10-24

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study.

N Engl J Med, 2022 Apr 11

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.

The New England journal of medicine, 2023 Jun 03

Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer.

The New England journal of medicine, 2023 Oct 21

Amivantamab plus Chemotherapy in NSCLC with Exon 20 Insertions.

JTO clinical and research reports, 2023 Aug 16

Real-World Response and Outcomes in Patients With NSCLC With Exon 20 Insertion Mutations.

The New England journal of medicine, 2023 Oct 23

Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer.

N Engl J Med, 2021 Jun 23

Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.

Future oncology (London, England), 2021 Jun 08

KEYNOTE-921: Phase III study of pembrolizumab plus docetaxel for metastatic castration-resistant prostate cancer.

Cancer cell, 2021 Jun 17

Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial.

The New England journal of medicine, 2023 Oct 22

Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma.

The New England journal of medicine, 2023 Oct 21

Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma.

Annals of oncology : official journal of the European Society for Medical Oncology, 2023 Oct 11

Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial.

Related Topics in Medical Oncology